Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Margetuximab by MacroGenics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Margetuximab is under clinical development by MacroGenics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
Margetuximab by MacroGenics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Margetuximab is under clinical development by MacroGenics and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to...
MGD-024 by MacroGenics for Hairy Cell Leukemia: Likelihood of Approval
MGD-024 is under clinical development by MacroGenics and currently in Phase I for Hairy Cell Leukemia. According to GlobalData, Phase...
MGD-024 by MacroGenics for Systemic Mastocytosis: Likelihood of Approval
MGD-024 is under clinical development by MacroGenics and currently in Phase I for Systemic Mastocytosis. According to GlobalData, Phase I...
Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...
Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...
Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
MGC-026 by MacroGenics for Bladder Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Metastatic Melanoma: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Small-Cell Lung Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
MGC-026 by MacroGenics for Metastatic Breast Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Metastatic Pancreatic Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Gastric Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Cervical Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
MGD-014 by MacroGenics for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
MGD-014 is under clinical development by MacroGenics and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Risk adjusted net present value: What is the current valuation of MacroGenics's Vobramitamab Duocarmazine?
Vobramitamab Duocarmazine is a monoclonal antibody conjugated commercialized by MacroGenics, with a leading Phase II program in Anal Cancer. According...
Enoblituzumab by MacroGenics for Rhabdomyosarcoma: Likelihood of Approval
Enoblituzumab is under clinical development by MacroGenics and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I drugs...
Enoblituzumab by MacroGenics for Neuroblastoma: Likelihood of Approval
Enoblituzumab is under clinical development by MacroGenics and currently in Phase I for Neuroblastoma. According to GlobalData, Phase I drugs...